L. Keith Henry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
L. Keith Henry has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Randy D. Blakely
1 shared publication
Latest Publications
- 1 March 2008
- Published by Elsevier in Molecular Pharmacology
- Vol. 73 (3) , 616-618
Distinctions between Dopamine Transporter Antagonists Could be Just around the Bend
Abuse of psychostimulants such as cocaine and amphetamines has a tremendous social and economic impact. Although replacement therapies are offered for addiction to opioids, nicotine, and alcohol, there is no approved replacement treatment for psychostimulant addiction. Recent studies on an emerging group of benztropine- and rimcazole-based compounds provide hope that replacement therapies for cocaine and amphetamine addiction may come in the near future. A new study (p. 813) now investigates the molecular interaction of the benztropine and rimcazole compounds with their target, the dopamine transporter, and provides an intriguing explanation as to why use of these compounds, unlike cocaine, do not lead to locomotor stimulation and drug discrimination behaviors in animal models.
- 1 March 2008
- Published by Elsevier in Molecular Pharmacology
- Vol. 73 (3) , 616-618
Distinctions between Dopamine Transporter Antagonists Could be Just around the Bend
Abuse of psychostimulants such as cocaine and amphetamines has a tremendous social and economic impact. Although replacement therapies are offered for addiction to opioids, nicotine, and alcohol, there is no approved replacement treatment for psychostimulant addiction. Recent studies on an emerging group of benztropine- and rimcazole-based compounds provide hope that replacement therapies for cocaine and amphetamine addiction may come in the near future. A new study (p. 813) now investigates the molecular interaction of the benztropine and rimcazole compounds with their target, the dopamine transporter, and provides an intriguing explanation as to why use of these compounds, unlike cocaine, do not lead to locomotor stimulation and drug discrimination behaviors in animal models.